日本薬理学会年会要旨集
Online ISSN : 2435-4953
WCP2018 (The 18th World Congress of Basic and Clinical Pharmacology)
セッションID: WCP2018_PO4-1-122
会議情報

Poster session
Reduction of the mitochondria-localized protein p13 protects against experimental parkinsonism
Norihito ShintaniNaoki InoueSae OguraYohei MorotaHitoshi Hashimoto
著者情報
会議録・要旨集 オープンアクセス

詳細
抄録

Parkinson's disease (PD) is caused by the specific loss of nigrostriatal dopaminergic neurons. Mitochondrial toxins produce cellular and behavioral deficits resembling those in PD patients. Causative gene products for familial PD are involved in mitochondrial function. Thus, targeting proteins regulating mitochondrial integrity could provide convincing strategies for PD therapeutics. A novel 13-kDa protein (p13), we have recently identified, was suggested to control mitochondrial function. Here, we study the mitochondrial function of p13 and its roles in PD pathogenesis using mitochondrial toxin-induced PD models. We show that p13 overexpression induces mitochondrial dysfunction and apoptosis, whereas its knockdown attenuates both in dopaminergic SH-SY5Y cells via the regulation of complex I. Importantly, we generate p13-deficient mice using the CRISPR/Cas9 system and observe that heterozygous p13 knockout prevents toxin-induced motor deficits and the loss of nigral dopaminergic neurons. Accordingly, these results suggest that manipulating p13 expression may be a promising avenue for therapeutic intervention in PD.

著者関連情報
© 2018 The Authors(s)
前の記事 次の記事
feedback
Top